A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

10.3K views

⸱

DOI:

10.3791/53758

⸱

January 22nd, 2017

 ,  ,  ,  ,  ,  ,  ,  ,  , 

In This Article

Summary

We present a biochemical and behavioral protocol to evaluate the efficacy of mitochondria-targeted water-soluble compounds for the treatment of Spinocerebellar ataxia type 1 (SCA1) and other cerebellar neurodegenerative diseases.

Abstract

Mitochondrial dysfunction plays a significant role in the aging process and in neurodegenerative diseases including several hereditary spinocerebellar ataxias and other movement disorders marked by progressive degeneration of the cerebellum. The goal of this protocol is to assess mitochondrial dysfunction in Spinocerebellar ataxia type 1 (SCA1) and assess the efficacy of pharmacological targeting of metabolic respiration via the water-soluble compound succinic acid to slow disease progression. This approach is applicable to other cerebellar diseases and can be adapted to a host of water-soluble therapies.

Ex vivo analysis of mitochondrial respiration is used to detect and quantify disease-related changes in mitochondrial function. With genetic evidence (unpublished data) and proteomic evidence of mitochondrial dysfunction in the SCA1 mouse model, we evaluate the efficacy of treatment with the water-soluble metabolic booster succinic acid by dissolving this compound directly into the home cage drinking water. The ability of the drug to pass the blood brain barrier can be deduced using high performance liquid chromatography (HPLC). The efficacy of these compounds can then be tested using multiple behavioral paradigms including the accelerating rotarod, balance beam test and footprint analysis. Cytoarchitectural integrity of the cerebellum can be assessed using immunofluorescence assays that detect Purkinje cell nuclei and Purkinje cell dendrites and soma. These methods are robust techniques for determining mitochondrial dysfunction and the efficacy of treatment with water-soluble compounds in cerebellar neurodegenerative disease.

Introduction

Mitochondria are the key producers of adenosine triphosphate (ATP), an essential coenzyme for cellular energy, with the majority of mitochondrial ATP produced through oxidative phosphorylation (OXPHOS) using the electron transport chain. The brain, given its high metabolic demands and its reliance on oxidative phosphorylation for powering neural activity, is highly susceptible to mitochondrial dysfunction. As a result, mitochondrial dysfunction is triggered during the aging process 1 and is implicated in the pathogenesis of multiple neurodegenerative diseases 2,3,<....

Access restricted. Please log in or start a trial to view this content.

Protocol

This protocol follows the IACUC guidelines at Skidmore College for working with mice.

1. Treatment with Water-soluble Compounds

  1. Dissolve succinic acid to a concentration of 0.75 mg/mL in cage drinking water. Note that any water-soluble compound of interest at the desired concentration could be substituted at this stage. Stir solution to make sure that the compound is fully dissolved.
  2. After mice reach the desired age of treatment, replace the home cage drinking water of the treatment condition group with the solution in step 1.1.
  3. Measure the weight of both treatment and control group water bottles daily to ensure that both treated....

Access restricted. Please log in or start a trial to view this content.

Results

Through pharmacological targeting of cerebellar mitochondria with succinic acid we are able to prevent mitochondrial dysfunction in a mouse model of the cerebellar neurodegenerative disease SCA1. The canonical electron donor of succinate dehydrogenase, succinic acid, was dissolved in home cage drinking water of SCA1 mice for one month, with behavioral assessment beginning during the second week of treatment and neuropathological assessment following treatment (Figure .......

Access restricted. Please log in or start a trial to view this content.

Discussion

If these methods are used as described, they are capable of detecting and alleviating oxidative phosphorylation-mediated mitochondrial dysfunction in cerebellar neurodegenerative disease mice models. The combined biochemical and behavioral assays are multifaceted methods for determining the extent of mitochondrial contribution to cerebellar neurodegenerative disease pathology. By treating mice with succinic acid to stimulate metabolism and boost mitochondrial function, we are able to show a rescue of cerebellar behaviora.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

We would like to thank Dr. Harry Orr at the University of Minnesota for his generous gift of transgenic mice. We would also like to thank the following Skidmore College alum for their work performing the preceding experiments: Monica Villegas, Porter Hall, Mitchell Spring, Nicholas Toker, Jenny Zhang, Chloe Larson and Cheyanne Slocum. Furthermore, we would like to thank Skidmore College for funding the development of these methods.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Adenosine diphosphateSigma AldrichA2754ADP
AscorbateSigma AldrichA7631
Bovine serum albuminSigma AldrichA2153BSA
4',6-Diamidino-2-phenylindoleSigma AldrichD9542DAPI
DigitoninSigma AldrichD141
DithiothreitolSigma AldrichD0632DTT
Donkey serumSigma AldrichD9663
GlutamateSigma Aldrich1446600
MalateSigma Aldrich6994
MannitolSigma AldrichM4125
ParaformaldehydeSigma AldrichP6148
Potassium-lactobionateBio-Sugars69313-67-3
RotenoneSigma AldrichR8875
SaponinSigma Aldrich47036
Succinic AcidSigma AldrichS3674
N,N,N′,N′-Tetramethyl-p-phenylenediamineSigma AldrichT7394TMPD
Triton X-100Sigma AldrichT9284
UreaSigma AldrichU0631
Vectashield mounting mediumVector LabsH-1000
Antibodies
11NQ antibody (anti-ataxin-1 )Servadio, et al. 1995, PMID: 7647801
Alexa Fluor 488 anti-mouse secondary antibodyLife TechnologiesA-11015
Alexa Fluor 594 anti-rabbit secondary antibodyLife TechnologiesA-11012
Calbindin antibody (goat)Santa CruzC-20
Animals
Control transgenic miceHarry Orr, Ph.D.A02Burright, et al. 1997, PMID: 9217978
SCA1 miceHarry Orr, Ph.D.B05Burright, et al. 1997, PMID: 9217978
Wildtype miceThe Jackson Laboratory001800
Equipment
ESM-100L microtomeERMASledge microtome
Fluoview FV1200 Confocal MicroscopeOlympus
Glycerol-gelatin slidesFD Neuro TechnologiesPO101
Hamilton syringeSigma AldrichVCAT 80465
OXYT1 Oxytherm Electrode Control UnitHansatech Instruments
P.T.F.E. paperCole-ParmerUX-08277-15
Rotallion RotarodPPP&Gcontact corresponding author for information
Ultimate 3000 HPLCDionex
Software
ImageJNational Institute of Healthhttp://imagej.nih.gov/ij/
Cell counter plugin (for ImageJ)National Institute of Healthhttp://rsb.info.nih.gov/ij/plugins/cell-counter.html
3P&G Rota-Rod v3.3.3 (rotarod software)PPP&Gcontact corresponding author for information
Phidget21.dll (required for rotarod software)DLL-Files.comhttps://www.dll-files.com/phidget21.dll.html

References

  1. Stucki, D. M., et al. Mitochondrial impairments contribute to Spinocerebellar ataxia type 1 progression and can be ameliorated by the mitochondria-targeted antioxidant MitoQ. Free Radic Biol Med. 97, 427-440 (2016).
  2. Breuer, M. E., Willems, P. H., Russel, F. G., Koopman, W. J., Smeitink, J. A.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Succinic Acid TreatmentBehavioral AssaysImmunofluorescence AssaysHPLC AnalysisMitochondrial RespirationCerebellar TissueNeurodegenerative Disease